LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Thursday reported a loss of $64.1 million in its fourth quarter.
The Los Angeles-based company said it had a loss of $1.71 per share. Losses, adjusted for stock option expense, were $1.03 per share.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.98 per share.
The biopharmaceutical company posted revenue of $20.1 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $19.7 million.
For the year, the company reported that its loss widened to $292 million, or $7.85 per share. Revenue was reported as $26.2 million.
Puma Biotech shares have decreased 37 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $61.95, an increase of 63 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PBYI at https://www.zacks.com/ap/PBYI